JNJ's $7B Charge: Why the Dividend King Still Shines

Johnson & Johnson reported third-quarter 2026 results that included a massive $7 billion charge, which caused GAAP earnings per share to plummet nearly 96%. The charge stems from two main items: a proposed $5.5 billion settlement to resolve talc litigation and expenses related to the Firefly Bio acquisition and Sail Biomedicines collaboration.

The talc litigation has been a cloud over J&J for years. The company spun off its consumer health business (now Kenvue) but retained liability for talc-related claims. The proposed settlement includes an initial $3 billion payment in 2027, with the remainder paid over future years. While costly, it could finally put this legal issue to rest.

The other portion of the charge relates to growth investments. J&J acquired Firefly Bio and entered a collaboration with Sail Biomedicines, both aimed at bolstering its pipeline in areas like oncology and immunology. These are strategic moves to drive future growth.

Despite the charge, J&J raised its full-year guidance for both revenue and earnings. Revenue grew nearly 6% in the quarter, showing that the core business remains robust. This resilience is typical of J&J, which has increased its dividend for 64 consecutive years, earning it the title of Dividend King.

For investors, the headline numbers look scary, but the underlying story is positive. The $7 billion charge is largely non-recurring, and the fact that J&J raised guidance despite it shows management's confidence in the business. The talc settlement, while expensive, removes a long-standing overhang and allows the company to focus on growth.

J&J's core business is performing well, with 6% revenue growth driven by its pharmaceutical and medical device segments. Healthcare spending is resilient to economic downturns, and J&J's diversified portfolio positions it well to benefit from aging populations and increasing healthcare needs.

The timing of the settlement is also favorable. By resolving the litigation now, during a relatively strong economy, J&J avoids the risk of facing a huge charge during a market downturn when investors are more sensitive to bad news. This proactive approach demonstrates strong management.

For dividend investors, J&J's 64-year streak of dividend increases is a testament to its financial strength and commitment to shareholders. The company generates ample cash flow to cover both the settlement payments and its dividend, ensuring that income investors can continue to rely on it.